AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

MEDICLINIC INTERNATIONAL PLC

Major Shareholding Notification Jan 29, 2019

4946_mrq_2019-01-29_cb6b3d1c-6e70-46f0-81bd-201e73d4e381.html

Major Shareholding Notification

Open in Viewer

Opens in native device viewer

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 4321O

Mediclinic International plc

29 January 2019

Mediclinic International plc

(Incorporated in England and Wales)

Company Number: 08338604

LSE Share Code: MDC

JSE Share Code: MEI

NSX Share Code: MEP

ISIN: GB00B8HX8Z88

LEI: 2138002S5BSBIZTD5I60

("Mediclinic", the "Company" or the "Group")

29 January 2019

Notification of Major Interest in Mediclinic International plc shares

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: Mediclinic International plc
1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)
Non-UK issuer
2. Reason for the notification (please mark the appropriate box or boxes with an "X")
An acquisition or disposal of voting rights x
An acquisition or disposal of financial instruments
An event changing the breakdown of voting rights
Other (please specify):
3. Details of person subject to the notification obligation
Name Mpilo Investment Holdings 2 (RF) (Pty) Ltd
City and country of registered office (if applicable) Stellenbosch, South Africa
4. Full name of shareholder(s) (if different from 3.)
Name N/A
City and country of registered office (if applicable)
5. Date on which the threshold was crossed or reached: 29/01/2019
6. Date on which issuer notified (DD/MM/YYYY): 29/01/2019
7. Total positions of person(s) subject to the notification obligation
% of voting rights attached to shares (total of 8. A) % of voting rights through financial instruments

(total of 8.B 1 + 8.B 2)
Total of both in % (8.A + 8.B) Total number of voting rights of issuer
Resulting situation on the date on which threshold was crossed or reached 0% 0% 737 243 810
Position of previous notification (if

applicable)
3.33% 3.33%
8. Notified details of the resulting situation on the date on which the threshold was crossed or reached
A: Voting rights attached to shares
Class/type of

shares

ISIN code (if possible)
Number of voting rights % of voting rights
Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)
Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)
Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)
Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)
0 0%
SUBTOTAL 8. A 0 0%
B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))
Type of financial instrument Expiration

date
Exercise/

Conversion Period
Number of voting rights that may be acquired if the instrument is

exercised/converted.
% of voting rights
SUBTOTAL 8. B 1 NIL NIL
B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))
Type of financial instrument Expiration

date
Exercise/

Conversion Period
Physical or cash

settlement
Number of voting rights % of voting rights
SUBTOTAL 8.B.2 NIL NIL
9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")
Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer
Full chain of controlled undertakings through which the voting rights and/or the

financial instruments are effectively held starting with the ultimate controlling natural person or legal entity (please add additional rows as necessary)
Name % of voting rights if it equals or is higher than the notifiable threshold % of voting rights through financial instruments if it equals or is higher than the notifiable threshold Total of both if it equals or is higher than the notifiable threshold
Phodiso Holdings Limited
Mpilo Investment Holdings 2 (RF) (Pty) Ltd 0% 0%
10. In case of proxy voting, please identify:
Name of the proxy holder N/A
The number and % of voting rights held N/A
The date until which the voting rights will be held N/A
11. Additional information
Mpilo Investment Holdings 2 RF (Pty) Ltd has been one of Mediclinic's empowerment partners since 2005 and the contractual arrangements of their investment expired on 31 December 2018.
Place of completion Stellenbosch, South Africa
Date of completion 29/01/2019

Mediclinic has a primary listing on the Main Market of the LSE in the United Kingdom, with secondary listings on the JSE in South Africa and the NSX in Namibia.

For further information, please contact:

Company Secretary, Link Company Matters Limited

Jayne Meacham / Caroline Emmet

+44 (0)20 7954 9569

Investor Relations, Mediclinic International plc

James Arnold, Head of Investor Relations

[email protected]

+44 (0)20 3786 8181

Media queries

FTI Consulting

Brett Pollard/Debbie Scott - UK

+44 (0)20 3727 1000

Sherryn Schooling - South Africa

+27 (0)21 487 9000

Registered address: 6th Floor, 65 Gresham Street, London, EC2V 7NQ, United Kingdom

Website: www.mediclinic.com 

Joint corporate brokers: Morgan Stanley & Co International plc and UBS Investment Bank

JSE sponsor: Rand Merchant Bank (A division of FirstRand Bank Limited)

NSX sponsor: Simonis Storm Securities (Pty) Ltd

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

END

HOLUKAORKRAAUAR

Talk to a Data Expert

Have a question? We'll get back to you promptly.